Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants

Noel C Chan, Vinai Bhagirath, Brian J Dale, John W Eikelboom

Research output: Contribution to journalReview ArticleOtherpeer-review

1 Citation (Scopus)


Four direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) have been shown to be at least as effective and safe as warfarin for the prevention of stroke in atrial fibrillation and the prevention and treatment of venous thromboembolism. Although they are administered in fixed doses without routine coagulation monitoring, measurement of anticoagulant effect or drug levels may be useful to determine if: anticoagulant effect is present in patients who are bleeding or require an urgent procedure or thrombolysis; levels are within usual on-therapy range in patients with recurrent thromboembolism during treatment; and levels are outside of the usual on-therapy range in patients with overdose or with extreme clinical characteristics. Traditional coagulation assays are widely available but lack sensitivity to detect clinically relevant anticoagulant effects, and lack accuracy in quantitating drug levels. Specific drug assays are less widely available but can accurately measure drug levels and should be preferred.
Original languageEnglish
Pages (from-to)1213-1223
Number of pages11
JournalExpert Review of Cardiovascular Therapy
Issue number11
Publication statusPublished - 2 Nov 2015
Externally publishedYes

Cite this